Here Is Why BioMarin (BMRN) Is Projected to Rally
This article from MSN discusses why BioMarin Pharmaceutical (BMRN) is projected to rally. It likely details factors contributing to this positive outlook for the company's stock, such as clinical trial results, new drug approvals, or financial performance.
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN
Perpetual Ltd significantly increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 425.7% in Q4, acquiring an additional 20,747 shares, bringing its total holdings to 25,621 shares valued at approximately $1.523 million. This increase occurred despite various other institutional investors making smaller adjustments to their BioMarin holdings, and two BioMarin EVPs conducting substantial insider sales. Analysts currently maintain a "Moderate Buy" consensus for BioMarin, with a target price of $90.00, though individual price targets vary.
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of BioMarin Pharmaceutical Inc. (BMRN), including its current stock price, historical data, analyst ratings, and company profile. As of April 2nd, the stock was trading at $55.50, reflecting a 3.04% decrease at close. The company, a biotechnology firm, specializes in developing therapies for life-threatening rare diseases with several products already commercialized and others in development.
BMRN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of BioMarin Pharmaceutical Inc. (BMRN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Voxzogo is highlighted as BMRN's largest revenue contributor, and the company's gross margin stands at 81.55%, with an operating margin of 22.48%. The analysis also benchmarks BMRN against industry leaders like ELAN and ARWR in terms of market capitalization and efficiency.
BioMarin Pharmaceutical Inc. (BMRN) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for BioMarin Pharmaceutical Inc. (BMRN), showing its current stock price, daily change, and historical performance. It also mentions the availability of analyst ratings (currently none) and earnings information (not available), and offers free trade alerts.
BioMarin Pharmaceutical Inc. (BMRN) rated overweight at Wells Fargo despite Voxzogo phase 2 study discontinuations
Wells Fargo maintained an overweight rating on BioMarin Pharmaceutical Inc. (BMRN) even though the company announced the discontinuation of two Phase 2 studies for its Duchenne Muscular Dystrophy (DMD) gene therapy, BMN 351, and its achondroplasia drug, Voxzogo, for children with hypochondroplasia. The firm believes the market largely anticipated these discontinuations. Despite these setbacks and revised 2026 Voxzogo revenue estimates, Wells Fargo slightly increased their price target due to pipeline adjustments for other BioMarin drugs.
What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders
BioMarin Pharmaceutical recently discontinued three Phase 2 Voxzogo studies due to safety concerns, yet simultaneously reported positive outcomes for the drug in other areas. Analysts and the company suggest Voxzogo's safety issues may be specific to certain uses, with BioMarin's overall outlook bolstered by its broader rare-disease portfolio. Investors should consider how these mixed results and future pipeline developments will shape BioMarin's investment narrative, especially given prior optimistic revenue and earnings forecasts that may now need reassessment.
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations
Wells Fargo has maintained an Overweight rating on BioMarin Pharmaceutical Inc. (BMRN) with a $75 price target, despite the discontinuation of three Phase 2 Voxzogo studies due to safety concerns. The firm believes the safety risk is indication-specific and views BMRN's outlook as less dependent on Voxzogo, considering the shares a buying opportunity. BioMarin also reported positive new results for Voxzogo in achondroplasia, showing sustained growth improvements and other benefits in children.
(BMRN) Volatility Zones as Tactical Triggers
This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN), identifying a neutral near-term sentiment and a mid-channel oscillation pattern. It highlights an exceptional 28.5:1 risk-reward setup targeting an 8.2% gain with a 0.3% risk. The report provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for different holding periods.
BMRN SEC Filings - Biomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for BioMarin Pharmaceutical Inc. (BMRN) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent filings detailing CEO stock options, the halting of certain VOXZOGO trials, key executive stock sales, and the company's 2025 financial performance, including a significant acquisition and the winding down of ROCTAVIAN. The platform also offers AI-powered summaries to help investors interpret these regulatory documents.
Exploring High Growth Tech Stocks In The US Market March 2026
The article explores high-growth tech stocks in the US market amid a fluctuating but promising long-term growth environment. It highlights the top 10 companies with strong revenue and earnings growth, such as Marker Therapeutics and Palantir Technologies, and provides detailed analyses on BioMarin Pharmaceutical, Kiniksa Pharmaceuticals International, and Klaviyo, showcasing their financial performance, strategic initiatives, and future potential.
Vanguard disaggregates holdings; BioMarin (NASDAQ: BMRN) shows 0 shares reported
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0 shares beneficially owned in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) due to an internal realignment. This realignment means certain Vanguard subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538. The filing, signed by Ashley Grim, Head of Global Fund Administration, indicates no voting or dispositive power over BioMarin shares by The Vanguard Group.
BioMarin Bests Ascendis in Appeal Battle Over Patent Suit Stays
The Federal Circuit Court of Appeals ruled in favor of BioMarin Pharmaceutical Inc., preventing Ascendis Pharma AS from using a procedural maneuver to delay a patent infringement lawsuit. This decision allows BioMarin to continue its efforts to block the launch of Ascendis' rival dwarfism treatment to BioMarin's Voxzogo injection. The court found Ascendis' method of dropping and refiling a complaint to reset a statutory deadline for seeking a mandatory stay to be a violation of common-law principles.
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin Pharmaceutical (BMRN) shares have dropped 13.6% since its last earnings report, underperforming the S&P 500. The company reported strong Q4 2025 earnings and sales, beating estimates, driven by Voxzogo and Enzyme Therapies, despite a significant inventory write-off for Roctavian. For 2026, BioMarin provided guidance anticipating continued revenue growth and adjusted EPS in the range of $4.95-$5.15, though analyst estimates have seen a downward revision post-announcement.
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN
Assenagon Asset Management S.A. significantly increased its stake in BioMarin Pharmaceutical Inc. ($BMRN) by 312.4% in the fourth quarter, now holding 1,419,067 shares valued at approximately $84.34 million. Despite this institutional accumulation, some executive VPs recently sold shares. Analyst consensus for BioMarin Pharmaceutical is a "Moderate Buy" with an average target price of $90.00.
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN
Swiss Life Asset Management Ltd significantly reduced its stake in BioMarin Pharmaceutical Inc. by 72.8% in the third quarter, selling over 54,000 shares. This move follows insider selling by key executives of BioMarin Pharmaceutical, who also decreased their holdings. Despite these sales, Wall Street analysts maintain a "Moderate Buy" consensus for BMRN, with an average target price of $90.
BioMarin (BMRN) CEO reports tax-withholding share disposition
BioMarin Pharmaceutical CEO Alexander Hardy reported a routine tax-withholding share disposition. On March 17, 2026, 4,252 shares of common stock were withheld at $56.05 per share to cover tax obligations. Following this transaction, Hardy directly holds 214,635 shares of BMRN.
BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO
This article from MSN discusses BioMarin Pharmaceutical's positive results from the ongoing trials of its drug, VOXZOGO. No further details are available in the provided content.
Top 3 Health Care Stocks That Are Set To Fly In March
This article identifies three healthcare stocks—Inspire Medical Systems (INSP), Profound Medical (PROF), and Biomarin Pharmaceutical (BMRN)—that are considered oversold with an RSI near or below 30, suggesting potential for an upward movement. Analyst ratings and recent financial performance for each company are highlighted, along with their current stock prices and 52-week lows. The article suggests that these undervalued companies present a buying opportunity for investors.
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140
BioMarin Pharmaceutical's EVP and Chief Technical Officer, Charles Greg Guyer, reported a tax-related disposition of 1,693 shares of common stock. These shares were withheld at a price of $56.05 each to cover tax obligations, a non-market transaction. Following this event, Guyer directly holds 84,140 common shares of BioMarin.
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes
BioMarin Pharmaceutical's EVP and Chief Legal Officer, George Eric Davis, reported a routine disposition of 1,273 common shares to cover tax obligations at $56.05 per share. This transaction is a standard tax-withholding event related to equity compensation, not an open-market sale. After this, Davis directly holds 78,560 shares, maintaining a substantial equity position in the company.
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax
BioMarin Pharmaceutical's EVP and CFO, Brian Mueller, reported a tax-related disposition of 2,117 common shares on March 17, 2026. These shares, valued at $56.05 each, were withheld to cover tax obligations, not representing an open-market sale. Following this transaction, Mueller directly holds 123,314 BioMarin common shares, indicating a routine event related to equity compensation.
Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN
Hudson Bay Capital Management LP significantly increased its stake in BioMarin Pharmaceutical Inc. by 31.8% in the third quarter, now holding 693,894 shares valued at approximately $37.58 million. This move is part of a broader trend of high institutional ownership in BioMarin, with other major funds also boosting their positions. Analysts maintain a "Moderate Buy" rating for the stock, with an average target price of $90, while the company's shares are currently trading around $55.
BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares
BioMarin Pharmaceutical's EVP and Chief R&D Officer, Gregory R. Friberg, received routine equity compensation including 19,150 shares of common stock and options for 45,600 shares on March 16, 2026. To cover tax obligations, 1,629 shares were disposed of at $56.05 per share on March 17, 2026. Following these transactions, Friberg directly owns 55,099 common shares, demonstrating his ongoing equity stake in the company.
BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax
BioMarin Pharmaceutical's EVP and Chief Commercial Officer, Cristin Hubbard, received significant equity grants including 15,410 shares as restricted stock units and stock options for 36,680 shares with an exercise price of $57.43. Following these grants, she disposed of 1,245 shares at $56.05 each for tax withholding purposes, rather than through an open-market sale. After all transactions, Hubbard directly holds 44,790 shares of BioMarin Common Stock.
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS)
This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN), and Ionis Pharmaceuticals (IONS). Analysts from Bank of America Securities, Jefferies, TD Cowen, and Cantor Fitzgerald have issued Buy ratings with significant upside potential for these stocks. Detailed price targets and analyst success rates are also provided for each company.
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO
BioMarin Pharmaceutical (BMRN) announced positive data from ongoing trials of VOXZOGO, its approved treatment for achondroplasia. The data indicates that early treatment, especially before the age of 2, maximizes benefits like height gains and improved body proportions, with kids under six months showing sustained improvements over four years. VOXZOGO has been used by over 5,000 children in more than 50 countries, with strong results reported in Japan, Europe, and the US.
BioMarin (NASDAQ: BMRN) CFO gets stock grants and tax share withholding
BioMarin Pharmaceutical's EVP and CFO, Brian Mueller, received routine equity compensation including a stock option grant for 44,600 shares and 18,740 restricted stock units. Additionally, 9,945 shares were withheld to cover tax obligations from a prior vesting event. These transactions resulted in Mueller directly holding 125,431 common shares and the new option for 44,600 shares.
[Form 4] BIOMARIN PHARMACEUTICAL INC Insider Trading Activity
BioMarin Pharmaceutical executive Charles Greg Guyer reported receiving new equity awards and a tax-related share withholding. On March 16, 2026, he was granted stock options for 35,680 shares and 14,990 restricted stock units. Additionally, 9,109 shares were withheld on March 13, 2026, to cover tax obligations.
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin Pharmaceutical will halt mid-stage trials for its bone disorder treatment, Voxzogo, after patients in trials for Turner Syndrome, SHOX-deficiency, and ACAN-deficiency experienced hip joint slippage. The company's shares dropped 4% following the announcement. BioMarin plans to continue testing the drug for Noonan syndrome and unexplained short stature, while Voxzogo remains approved for achondroplasia.
BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ)
BioMarin Pharmaceutical's shares dropped by 4% after the company announced the discontinuation of dosing and enrollment in its Phase 2 trials for Voxzogo. This decision affects trials targeting Turner syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency, and was made due to several slipped capital femoral epiphysis (SCFE) events observed in two ongoing studies.
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts
BioMarin has halted dosing and enrollment in three Phase 2 studies of its drug Voxzogo for Turner syndrome, SHOX-deficiency, and aggrecan-deficiency due to reports of slipped capital femoral epiphysis (SCFE) events in investigator-sponsored trials. While BioMarin's own studies and the achondroplasia trials have not shown SCFE events, this move introduces uncertainty as competition for Voxzogo in achondroplasia, its key indication, is increasing with the FDA approval of Ascendis Pharma's Yuviwel. The company will continue Voxzogo studies for Noonan syndrome and idiopathic short stature, implementing new safety measures.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) appears to be a compelling value investment opportunity, identified through a "Decent Value" screen. The company exhibits attractive valuation metrics, strong financial health with low debt and high liquidity, and excellent profitability with industry-leading margins. While past EPS growth was negative, analysts project significant future growth, which could act as a catalyst for a re-rating of the stock.
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia
New multi-year data on BioMarin Pharmaceutical's drug VOXZOGO for achondroplasia in young children indicates durable gains in skeletal growth and body proportionality when treatment starts before age 2. This early use data strengthens the case for earlier diagnosis and treatment, potentially broadening the patient pool and influencing future demand, reimbursement, and treatment guidelines. While there are risks related to its accelerated approval and practical requirements, analysts note BioMarin is trading at a discount, and this data could support long-term growth forecasts and its rare-disease portfolio's commercial potential.
Braidwell LP Acquires Shares of 528,000 BioMarin Pharmaceutical Inc. $BMRN
Braidwell LP has acquired a new stake of 528,000 shares in BioMarin Pharmaceutical Inc., valued at approximately $28.6 million. This acquisition, disclosed in a recent 13F filing, means Braidwell LP now owns roughly 0.27% of the biotechnology company. Institutional investors collectively hold 98.71% of BioMarin stock, with many, including AQR Capital Management and Capital Research Global Investors, significantly increasing their positions.
Boone Capital Management LLC Sells 118,903 Shares of BioMarin Pharmaceutical Inc. $BMRN
Boone Capital Management LLC reduced its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 26.6% in the third quarter, selling 118,903 shares and now holding 328,546 shares valued at $17.8 million. Two executive VPs also sold a combined 22,812 shares, reducing their positions by 14-17%. Despite these sales, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $90.00.
Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness
BioMarin Pharmaceutical (BMRN) has experienced prolonged share price weakness, with declines over the past week, month, year, three years, and five years. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued, estimating an intrinsic value of $196.11 per share compared to its recent price of $58.51. However, its current P/E ratio of 32.25x is higher than the industry average and Simply Wall St's Fair Ratio, indicating it might be overvalued by that metric.
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) received FDA approval for the expanded use of PALYNZIQ to include adolescents aged 12 and older with phenylketonuria (PKU). This approval addresses the challenges teenagers face in maintaining restrictive PKU diets, leveraging data from the Phase 3 PEGASUS study which showed significant reductions in blood phenylalanine levels. The company is also seeking similar approval from the European Medicines Agency.
EVP Of BioMarin Pharmaceutical Sold $996K In Stock
Greg Charles Guyer, EVP at BioMarin Pharmaceutical (NASDAQ: BMRN), sold 16,486 shares of the company's stock for a total of $996,743, according to a recent SEC filing. BioMarin Pharmaceutical is a biotechnology company focused on rare genetic diseases, with notable revenue growth but lower profitability and market capitalization compared to industry peers. The article highlights the importance of observing insider transactions alongside other financial metrics when evaluating investment opportunities.
Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026
Jefferies has reiterated a "Buy" rating on BioMarin Pharmaceutical Inc. (BMRN) following the company's release of "viable and positive" trial data. This move signals continued analyst confidence in BMRN's long-term value, despite a minor short-term stock dip of 1.6% post-news. The reiteration provides an endorsement for existing investors, highlighting the importance of monitoring upcoming clinical updates and regulatory milestones rather than expecting an immediate price catalyst.
Jefferies reiterates Buy on BioMarin stock after DMD trial data
Jefferies has reiterated a Buy rating and a $103.00 price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) after positive Phase 1/2 trial data for BMN 351 in Duchenne muscular dystrophy (DMD). The data showed a dose-dependent increase in dystrophin expression, with the 9mg/kg cohort achieving 3.55% normal dystrophin, which is comparable to competitor DYNE-251 despite the small sample size. Currently trading at $60.81, BioMarin appears undervalued, with analysts foreseeing significant upside potential.
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Pharmaceutical Inc. announced new data on its drug VOXZOGO (vosoritide) for children with achondroplasia, highlighting the positive impact of early treatment on proportionality, arm span, and growth. The findings suggest that starting treatment before age two leads to durable and sustained improvements in skeletal health outcomes, reinforcing VOXZOGO's established efficacy and safety profile. The data will be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN
Capital Research Global Investors has significantly increased its stake in BioMarin Pharmaceutical Inc. (BMRN) by purchasing an additional 2,145,717 shares, raising its total holdings to 2,537,596 shares. Several other hedge funds also adjusted their positions, mostly increasing their holdings in the biotechnology company. Wall Street analysts have issued mixed ratings for BMRN, with a consensus of "Moderate Buy" and a target price of $89.43, while an insider recently sold a portion of their shares.
BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook
BioMarin Pharmaceutical Inc. (BMRN) saw its revenue grow by 13% in 2025, driven by strong performance from Voxzogo and enzyme therapies. Key catalysts for 2026 include major phase III readouts, the acquisition of Amicus, and upcoming new product launches. The company's commercial strategy focuses on expanding access, managing competition, and leveraging operational synergies for future growth.
BofA cuts BioMarin stock price target to $85 on Voxzogo outlook
BofA Securities has lowered its price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $85 from $97, while maintaining a Buy rating, citing more conservative assumptions for the Voxzogo franchise. The firm removed Voxzogo's terminal value from its valuation model and expects BioMarin's acquisition of Amicus to reduce exposure to Voxzogo competitive headwinds. Despite 12 analysts revising earnings downwards, the company has a strong financial health score and upcoming data catalysts, with several other analysts also adjusting price targets and ratings.
PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN)
BioMarin Pharmaceutical Inc. (BMRN) recently received FDA approval to expand PALYNZIQ's use to pediatric phenylketonuria patients aged 12 and older, a move that broadens its market but is subject to REMS restrictions due to immune-mediated risks. This expansion reinforces BioMarin's strategy of deepening existing franchises, aligning with recent regulatory updates like VOXZOGO's Canadian approval. While this offers growth potential, investors should consider the ongoing challenges of pricing pressure, reimbursement decisions, and the company's product concentration risk.
Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026
Leerink Partners has maintained its Market Perform rating on BioMarin Pharmaceutical Inc. (BMRN) as of March 09, 2026, signaling caution regarding the commercial rollout and uptake of its drug, Voxzogo. The firm did not issue a new price target, emphasizing neutral near-term expectations and advising investors to monitor Voxzogo's commercial dynamics before making significant investment changes. Meyka AI independently rates BMRN with a B+ grade, factoring in various financial metrics and market context.
WINTON GROUP Ltd Has $6.69 Million Stake in BioMarin Pharmaceutical Inc. $BMRN
WINTON GROUP Ltd significantly increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2,835% in Q3, now owning 123,474 shares valued at $6.69 million. BioMarin Pharmaceutical trades at $61.12, has a market cap of $11.75 billion, and a "Moderate Buy" consensus rating from analysts with an average target price of $89.64. Insider trading activity included an EVP selling 6,326 shares, while institutional investors hold roughly 98.71% of the stock.
Assessing BioMarin Pharmaceutical (BMRN) Valuation After FDA Expands PALYNZIQ Label For Pediatric PKU
BioMarin Pharmaceutical (BMRN) is under valuation scrutiny following the FDA's expansion of PALYNZIQ's label to include pediatric PKU patients aged 12 and older. Despite recent share price momentum and an estimated intrinsic discount, the company's P/E ratio is higher than industry averages, leading to questions about whether it represents a margin-of-safety opportunity or a valuation trap. Investors are advised to consider the company's rewards and risks, including competition and R&D spending, before making investment decisions.
Leerink Partners reiterates Market Perform on BioMarin stock at $62
Leerink Partners has reiterated a Market Perform rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a $62 price target, noting the stock trades near this target but below the Street high of $120. The firm discussed BioMarin's growth strategy, innovation, and value pillars, acknowledging the company's revenue growth, projected future growth, and ongoing pipeline development. Despite some caution regarding competitive dynamics for Voxzogo, the firm highlighted the potential benefits of the pending Amicus acquisition and provided insights from the company's management at the Global Healthcare Conference.
